Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 123,770

Document Document Title
WO/2017/075013A1
The present invention provides methods and compositions for promoting recovery of function from neurologic injury, such as ischemic injury caused by acute stroke.  
WO/2017/072584A1
The present application relates to a method of treating a migraine headache in a patient by administering a pharmaceutical composition including rizatriptan or pharmaceutically acceptable salts thereof contained in a unit dose.  
WO/2017/073485A1
The present invention provides a novel peptide having the property of specifically accumulating in and directly acting on a glioma. The present invention is a peptide represented by any one of the following (a) to (c): (a) a peptide form...  
WO/2017/072721A1
The disclosures herein relate to novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associate...  
WO/2017/075119A1
A composition comprising at least one AAV vector formulated for intrathecal delivery to the central nervous system is described. The composition comprises at least one expression cassette which contains sequences encoding an immunoglobul...  
WO/2017/072099A1
The present invention relates to the compound ((2R,2'R)-bis(((tetrahydro-2H-pyran-4- carbonyl)oxy)methyl) 1,1'-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment o...  
WO/2017/072225A1
The invention concerns a pet food or a pet supplement comprising a synergistically-effective antioxidant composition comprising an extract of Vitis vinifera and an extract of Vaccinium angustifolium, wherein said composition comprises at...  
WO/2017/073710A1
The purpose of the present invention is to provide a compound that is effective as a prophylactic agent or a therapeutic agent for various diseases and symptoms associated with the orexin receptor, as well as to provide a medical usage t...  
WO/2017/071576A1
The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of gene...  
WO/2017/072083A1
The present invention relates to compounds of formula (I), wherein R1' is methyl; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, e...  
WO/2017/071716A1
A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is di...  
WO/2017/075192A1
The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof c...  
WO/2017/075580A1
Compositions and methods for treating, alleviating, and/or preventing one or more symptoms associated with axonal degeneration in individuals in need thereof, such as individuals with peroxisomal disorders and leukodystrophies include on...  
WO/2017/075540A9
Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologi...  
WO/2017/071799A1
The invention relates to methods of treating a central nervous system disorder in a subject, comprising reducing the level of LPA in the brain of said subject.  
WO/2017/072816A1
The present invention addresses the problem of providing a therapeutic agent for fibrotic diseases of the organs that can effectively suppress (or prevent) organ fibrosis such as renal fibrosis. The present invention solves this problem ...  
WO/2017/070793A1
The present application relates to novel fluorinated heterocycle derivatives or compounds of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention ...  
WO/2017/075468A1
This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions embraced by the invention exh...  
WO/2017/070731A1
The present invention relates to compositions and methods for treating Alzheimer's disease. In particular, the present invention relates to the use of muramyl dipeptide crosslinked to form a microparticle for the treatment of Alzheimer's...  
WO/2017/075340A1
Provided herein are salts of (S)-2-amino-3 -methyl-butyric acid (2R,3R, 1 1bR)-3-isobutyl- 9, 10-dimethoxy-1, 3, 4,6,7,11b-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation,...  
WO/2017/073516A1
An adhesive skin patch provided with a support and an adhesive agent layer laminated on at least one surface of the support, wherein the adhesive agent layer contains at least one component selected from the group consisting of fentanyl ...  
WO/2017/075535A1
The present disclosure provides methods for treating a neurodegenerative condition or situation in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising ghrelin or a ghrelin variant.  
WO/2017/075540A1
Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologi...  
WO/2017/075607A1
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.  
WO/2017/072723A1
The disclosures herein relate to heterocyclic calcitonin gene-related peptide (CGRP) antagonists of formula (I) useful in the treatment or prevention of cerebrovascular or vascular disorders such as migraine.  
WO/2017/075222A1
Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium chann...  
WO/2017/070738A1
The present disclosure relates generally to the treatment of diseases and conditions exacerbated by signalling via the erythropoietin- producing-hepatoma receptor kinases EphA4 and to agents useful in such treatment.  
WO/2017/072984A1
The present invention addresses the problem of providing a novel therapeutic agent and treatment method for amyotrophic disorders, more specifically, a therapeutic agent and treatment method for neurogenic atrophy disorders such as amyot...  
WO/2017/070795A1
The present application relates to novel fluorinated amide derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chr...  
WO/2017/072722A1
The disclosures herein relate to novel compounds of formula (I) wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated wi...  
WO/2017/071479A1
Disclosed is a glutamine acyl cyclase inhibitor, and the structure thereof is as shown in formula (I). The glutamine acyl cyclase inhibitor (QC inhibitor) provided in the present invention is designed according to the target enzyme prote...  
WO/2017/071889A1
The present invention relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the trea...  
WO/2017/072335A1
The present invention relates to a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein said patients are treated with a tyrosine kinase inhibitor or mas...  
WO/2017/070796A1
The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic n...  
WO/2017/072219A1
The invention relates to a nutritional or therapeutic agent which includes a mixture of molecules obtained from Vitis vinifera and Vaccinium angustifolium , including: at least 1 % of catechins and epicatechins, given as a percentage by ...  
WO/2017/069662A1
An agent exhibiting anti-stress, anxiolytic and anti-depression activity, and a composition based thereon. The invention relates to the field of pharmaceutical science, and specifically to chemical compounds based on lithium salts, and p...  
WO/2017/068069A1
The invention relates to a composition comprising a mixture of at least three molecules: a mono-caffeoylquinic acid, a di-caffeoylquinic acid and oleuropein. Said composition is particularly used as a medicament or a nutrition product fo...  
WO/2017/068070A1
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also a...  
WO/2017/070573A1
Optogenetic and chemogenetic actuators are critical for deconstructing the neural correlates of behavior. However, these tools have several drawbacks, including invasive modes of stimulation or slow on/off kinetics. These disadvantages h...  
WO/2017/070068A1
The invention provides a crystalline form of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hyd roxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl ]ethanone, and pharmaceutical compositions thereof. The invention furt...  
WO/2017/068583A1
A method of treating a neurodegenerative disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a CXCR4 antagonist and lactate or/and zinc. Kits for treating same are also disclosed.  
WO/2017/068057A1
The invention relates to a composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health pro...  
WO/2017/068090A1
The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in ...  
WO/2017/070293A1
The present disclosure relates to pharmaceutical compositions comprising an effective amount of L-dopa and an effective amount of a phosphodiesterase 9 inhibitor, and methods for treating Parkinson's disease or Parkinsonism, comprising a...  
WO/2017/069279A1
Provided is a compound that has an effect of inhibiting RIP1 kinase and is useful as a prophylactic or therapeutic agent for Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiples sclerosis, chronic nephropathy, a...  
WO/2017/069182A1
The purpose of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA ...  
WO/2017/068089A3
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a l...  
WO/2017/068388A3
The present invention relates to the use of the synthetic PnTx-19 peptide for preparing analgesic medicinal drugs for the treatment of patients suffering from neuropathic pain, nociceptive pain (sensitisation of nociceptors by prostaglan...  
WO/2017/069270A1
Provided is a novel compound or a pharmaceutically acceptable salt thereof that is useful for treating or preventing, on the basis of the PAM effects of the GABAB receptor, diseases such as autism spectrum disorder, fragile X syndrome, s...  
WO/2017/067870A1
The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain.  

Matches 301 - 350 out of 123,770